Vesnarinone (INN) is a cardiotonic agent.[1] A mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of heart failure.
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H25N3O4 |
Molar mass | 395.459 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
References
edit- ^ Cavusoglu E, Frishman WH, Klapholz M (June 1995). "Vesnarinone: a new inotropic agent for treating congestive heart failure". Journal of Cardiac Failure. 1 (3): 249–257. doi:10.1016/1071-9164(95)90030-6. PMID 9420657.
External links
edit- Media related to Vesnarinone at Wikimedia Commons